Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations

Anti-CD20 therapies have established efficacy in the treatment of immune-mediated neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed therapies, is relatively inexpensive compared to newer anti-CD20 molecules, is available in many countries, and has been used off-label in pediatric patients with neuroimmune conditions. The objective of this paper is to describe the experience with rituximab in pediatric multiple sclerosis and other inflammatory immune-mediated disorders of the central nervous system (CNS), and to define a protocol for its use in clinical practice, in particular addressing doses, interval of administration, duration of treatment, and tests to perform at baseline and during follow-up.

[1]  E. Waubant,et al.  Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis , 2020, Annals of neurology.

[2]  E. Yeh,et al.  Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease , 2020, Developmental medicine and child neurology.

[3]  T. Olsson,et al.  Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients , 2020, Annals of neurology.

[4]  F. Piehl,et al.  Rituximab treatment for multiple sclerosis , 2020, Multiple sclerosis.

[5]  J. Pelletier,et al.  Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases , 2020 .

[6]  T. Olsson,et al.  Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. , 2020, JAMA neurology.

[7]  M. Sormani,et al.  Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. , 2019, Multiple sclerosis and related disorders.

[8]  Tiansong Zhang,et al.  Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis. , 2019, Multiple sclerosis and related disorders.

[9]  O. Boyman,et al.  Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders , 2019, Front. Immunol..

[10]  R. Fuleihan,et al.  Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases , 2019, Pediatric Rheumatology.

[11]  J. Sejvar,et al.  Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis , 2019, Neurology.

[12]  F. Yin,et al.  Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Diseases in Children in Central South China: Clinical Features, Treatments, Influencing Factors, and Outcomes , 2019, Front. Neurol..

[13]  F. Piehl,et al.  Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis , 2019, European journal of neurology.

[14]  A. Garoufi,et al.  Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis , 2019, Case reports in pediatrics.

[15]  J. Standing,et al.  Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases , 2019, British journal of clinical pharmacology.

[16]  Daishi Tian,et al.  Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. , 2019, Autoimmunity reviews.

[17]  A. Chan,et al.  Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course , 2019, Therapeutic advances in neurological disorders.

[18]  R. Gold,et al.  Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders , 2018, Journal of Neurology.

[19]  E. Waubant,et al.  Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US , 2018, Neurology.

[20]  H. Eibel,et al.  BAFF and BAFF-Receptor in B Cell Selection and Survival , 2018, Front. Immunol..

[21]  T. Tanimoto,et al.  Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients , 2018, Multiple sclerosis.

[22]  Yeseul Kim,et al.  Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[23]  R. Manz,et al.  Targeting B Cells and Plasma Cells in Autoimmune Diseases , 2018, Front. Immunol..

[24]  O. Ciccarelli,et al.  Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease , 2018, JAMA neurology.

[25]  F. Piehl,et al.  Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis , 2018, JAMA neurology.

[26]  V. Fung,et al.  Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[28]  A. Traboulsee,et al.  Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.

[29]  V. Damato,et al.  Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. , 2016, JAMA neurology.

[30]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome , 2016, Journal of Neuroinflammation.

[31]  D. Centonze,et al.  Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study , 2016, Journal of Neurology.

[32]  F. Piehl,et al.  Rituximab versus fingolimod after natalizumab in multiple sclerosis patients , 2016, Annals of neurology.

[33]  F. Piehl,et al.  Rituximab in paediatric onset multiple sclerosis: a case series , 2016, Journal of Neurology.

[34]  M. Nolan,et al.  Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[35]  B. Banwell,et al.  Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease , 2014, Neurology.

[36]  E. Waubant,et al.  B-cell depletion in children with neuroimmunologic conditions , 2014, Neurology.

[37]  E. Waubant,et al.  Rituximab use in pediatric central demyelinating disease. , 2014, Pediatric neurology.

[38]  Chunshui Yu,et al.  Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica , 2013, Neurology.

[39]  E. Frohman,et al.  Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success , 2012, Multiple sclerosis.

[40]  A. Ghezzi,et al.  Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis , 2012, Multiple sclerosis.

[41]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[42]  P. Calabresi,et al.  Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.

[43]  J. Hunter,et al.  Spectrum of Pediatric Neuromyelitis Optica , 2008, Pediatrics.

[44]  B. Weinshenker,et al.  CNS aquaporin-4 autoimmunity in children , 2008, Neurology.

[45]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[46]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.